Ad is loading...
BEAM
Price
$24.90
Change
+$1.32 (+5.60%)
Updated
Nov 22, 03:16 PM (EDT)
102 days until earnings call
PROK
Price
$1.72
Change
-$0.02 (-1.15%)
Updated
Nov 22, 03:34 PM (EDT)
130 days until earnings call
Ad is loading...

BEAM vs PROK

Header iconBEAM vs PROK Comparison
Open Charts BEAM vs PROKBanner chart's image
Beam Therapeutics
Price$24.90
Change+$1.32 (+5.60%)
Volume$400
CapitalizationN/A
ProKidney
Price$1.72
Change-$0.02 (-1.15%)
Volume$318
CapitalizationN/A
BEAM vs PROK Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PROK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BEAM vs. PROK commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and PROK is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (BEAM: $23.58 vs. PROK: $1.74)
Brand notoriety: BEAM and PROK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 94% vs. PROK: 33%
Market capitalization -- BEAM: $2.03B vs. PROK: $222.66M
BEAM [@Biotechnology] is valued at $2.03B. PROK’s [@Biotechnology] market capitalization is $222.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whilePROK’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • PROK’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than PROK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while PROK’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 6 bearish.
  • PROK’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than PROK.

Price Growth

BEAM (@Biotechnology) experienced а -10.38% price change this week, while PROK (@Biotechnology) price change was -19.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.98%, and the average quarterly price growth was +4.01%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

PROK is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.03B) has a higher market cap than PROK($223M). PROK YTD gains are higher at: -2.247 vs. BEAM (-13.373). PROK has higher annual earnings (EBITDA): -131.07M vs. BEAM (-160.83M). BEAM has more cash in the bank: 926M vs. PROK (407M). PROK has less debt than BEAM: PROK (6.44M) vs BEAM (162M). BEAM has higher revenues than PROK: BEAM (350M) vs PROK (0).
BEAMPROKBEAM / PROK
Capitalization2.03B223M909%
EBITDA-160.83M-131.07M123%
Gain YTD-13.373-2.247595%
P/E RatioN/AN/A-
Revenue350M0-
Total Cash926M407M228%
Total Debt162M6.44M2,516%
TECHNICAL ANALYSIS
Technical Analysis
BEAMPROK
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
61%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
61%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
66%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 9 days ago
71%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 5 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PROK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFMAX34.870.32
+0.93%
Davidson Multi-Cap Equity A
IENYX32.550.23
+0.71%
Invesco Energy Y
FMUFX14.940.05
+0.34%
Federated Hermes Muni and Stock Adv F
JHDRX18.660.03
+0.16%
JPMorgan Hedged Equity 2 R6
VKSGX10.96N/A
N/A
Virtus KAR Small-Mid Cap Value R6

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-3.72%
CRSP - BEAM
74%
Closely correlated
-2.05%
NTLA - BEAM
66%
Closely correlated
+5.18%
DNLI - BEAM
64%
Loosely correlated
-0.82%
RXRX - BEAM
62%
Loosely correlated
-4.80%
EDIT - BEAM
62%
Loosely correlated
-1.66%
More

PROK and

Correlation & Price change

A.I.dvisor tells us that PROK and BEAM have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PROK and BEAM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROK
1D Price
Change %
PROK100%
+5.45%
BEAM - PROK
32%
Poorly correlated
-3.72%
PRME - PROK
32%
Poorly correlated
-0.67%
RXRX - PROK
31%
Poorly correlated
-4.80%
ADPT - PROK
29%
Poorly correlated
-1.13%
CRBU - PROK
29%
Poorly correlated
+1.02%
More